top of page
Gotham__Org Gotham White.png

Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - Disease Related Symptoms

For patients with Kidney cancer; a 9 item scale of Disease Related Symptoms



Below are the details for the FKSI-DRS measure:


Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - Disease Related Symptoms (FKSI-DRS)






Kidney cancer patients 18 years and older


Past 7 days


5 point Likert-type scale


Paper and electronic


Self-administration and interview when applicable


Kidney cancer symptom index


Less than 5 minutes


Manual scoring template, some items are reverse scored. Total scores available.


Language Availability

Available translations of the FKSI-DRS can be obtained by registering for permission. Users are not permitted to translate the FKSI-DRS without permission from Permission from to translate the FKSI-DRS may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system.

Please contact us for more information.

Language Availability


Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained.

Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use.

To license an available version of this measure for commercial or non-commercial use, please complete our registration form. All of the information provided in the form will be kept strictly confidential. For questions, please contact us.

Selected References

Selected References

Bukowski, R., Cella, D., Gondek, K., Escudier, B. Effects of sorafenib on symptoms and quality of life results from a large randomized placebo-controlled study in renal cancer.  American Journal of Clinical Oncology; 2007: 30(3): 220-227. doi: 10.1097/01.coc.0000258732.80710.05.  

Butt, Z., Peipert, D., Webster, K., Chen, C., & Cella, D. General population norms for the functional assessment of cancer therapy – kidney symptom index (FKSI).  Cancer 2013; 119(2): 429-437. doi: 10.1002/cncr.27688.

Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer?  A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535.  doi: 10.108/CNV-120022366.  

Cella, D., Yount, S., Brucker, P., Du, H., Bukowski, R., Vogelzang, N., Bro, W. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value in Health 2007; 10(4): 285-293.  doi: 10.1111/j.1524-4733.2007.00183.x.  

Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J.  Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer.  Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. 

Cella, D., Escudier, B., Rini, B., Chen, C., Bhattacharyya, H., Tarzai, J., Rosbrook, B., Kim, S., & Motzer, R. Patient-reported outcomes for axitinib v sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. British Journal of Cancer 2013; 108(8): 1571–1578.  doi: 10.1038/bjc.2013.

Luo, X., Cappelleri, J., Cella, D., Li, J., Charbonneau, C., Kim, S., Chen, I., & Motzer, R.  Using the Rasch model to validate and enhance the interpretation of the functional assessment of cancer therapy-kidney symptom index-disease related symptoms scale.  Value in Health 2009; 12(4): 580-586.  doi: 10.1111/j.1524-4733.2008.00473.x.

Motzer, R. , Hutson, T., Olsen, M., Hudes, G., Burke, J., Edenfield, W., Wilding, Agarwal, N., Thompson, J., Cella, D., Bello, A., Korytowksy, B., Yuan, J., Valota, O., Martell, B., Hariharan, S., & Figlin, R.  Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.  Journal of Clinical Oncology 2012; 30(12): 1371-1377.  doi: 10.1200/JCO.2011.36.4133.

Rini, B., Wilding, G., Hudes, G., Stadler, W., Kim, S., Tarazi, J., Rosbrook, B., Trask, P., Wood, L., & Dutcher, J.  Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma.  Journal of Clinical Oncology 2009; 27(27): 4462-4468.  doi: 10.1200/JCO.2008.21.7034.

Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320.

Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232.

Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85.

Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191.

Related Measures

Related Measures


Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 15 Item Version


National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 19 Item Version


Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 10 Item Version

bottom of page